3-D Conformal HDR Brachytherapy asMonotherapy for Localized Prostate Cancer

Martin, T; Baltas, D; Kurek, R; Röddiger, S; Kontova, M; Anagnostopoulos, G; Dannenberg, T; Buhleier, T; Skazikis, G; Tunn, U; Zamboglou, N

dc.contributor.author	Martin, T	en
dc.contributor.author	Baltas, D	en
dc.contributor.author	Kurek, R	en
dc.contributor.author	Röddiger, S	en
dc.contributor.author	Kontova, M	en
dc.contributor.author	Anagnostopoulos, G	en
dc.contributor.author	Dannenberg, T	en
dc.contributor.author	Buhleier, T	en
dc.contributor.author	Skazikis, G	en
dc.contributor.author	Tunn, U	en
dc.contributor.author	Zamboglou, N	en
dc.date.accessioned	2014-03-01T01:53:15Z
dc.date.available	2014-03-01T01:53:15Z
dc.date.issued	2004	en
dc.identifier.uri	https://dspace.lib.ntua.gr/xmlui/handle/123456789/26899
dc.subject	Acute Toxicity	en
dc.subject	Pilot Study	en
dc.subject	Prostate Cancer	en
dc.subject	Prostate Specific Antigen	en
dc.subject	Three Dimensional	en
dc.subject	Ultrasound	en
dc.subject	Dose Volume Histogram	en
dc.subject	gleason score	en
dc.subject	High Dose Rate	en
dc.subject	Real Time	en
dc.title	3-D Conformal HDR Brachytherapy asMonotherapy for Localized Prostate Cancer	en
heal.type	journalArticle	en
heal.identifier.primary	10.1007/s00066-004-1215-4	en
heal.identifier.secondary	http://dx.doi.org/10.1007/s00066-004-1215-4	en
heal.publicationDate	2004	en
heal.abstract	Purpose: Pilot study to evaluate feasibility, acute toxicity and conformal quality of three-dimensional (3-D) conformal high-dose- rate (HDR) brachytherapy as monotherapy for localized prostate cancer using intraoperative real-time planning. Patients and Methods: Between 05/2002 and 05/2003, 52 patients with prostate cancer, prostate-specific antigen (PSA) = 10 ng/ml, Gleason score = 7 and clinical stage = T2a were treated. Median PSA	en
dc.identifier.doi	10.1007/s00066-004-1215-4	en